Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04946656 · ClinicalTrials.gov registry record · NA
A Study of SPG Block for Opioid Withdrawal
A NA study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT04946656: Completed NA study, sponsored by New York State Psychiatric Institute.
NCT04946656 is a NA study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04946656, a NA study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Medication is the most efficacious treatment of an opioid use disorder, including methadone, buprenorphine, and naltrexone. However, many patients experience withdrawal symptoms, which prevents them from being successfully inducted onto medication for opioid use disorder. This study is a pilot study investigating whether blocking the SPG helps reduce withdrawal symptoms in OUD. This study does not involve treatment or induction onto medications. It is a proof of principal study only. We will recruit non-treatment seeking subjects with OUD who are admitted to the research unit for all procedures.
Primary Outcome
We will measure the percent of screened participants who agree to enroll as part of the feasibility study
Interventions
- PROCEDURE sphenopalatine ganglion block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-02-03 |
| Est. Completion | 2025-09-03 |
| Phase | NA |
What the finished NCT04946656 record still lists
NCT04946656 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which sphenopalatine ganglion block is the first listed.
NCT04946656 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04946656 about?
NCT04946656 is a clinical study titled "A Study of SPG Block for Opioid Withdrawal". Medication is the most efficacious treatment of an opioid use disorder, including methadone, buprenorphine, and naltrexone. However, many patients experience withdrawal symptoms, which prevents them from being successfully inducted onto medication for opioid use disorder. This study is a pilot study...
What is the current status of trial NCT04946656?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2023-02-03. Estimated completion is 2025-09-03.
What interventions are being tested in trial NCT04946656?
The interventions under investigation include: sphenopalatine ganglion block (PROCEDURE).
Who is sponsoring clinical trial NCT04946656?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04946656's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI